Floatz logo

Abemaciclib

CHEK2 Gene Mutation

University of California, DavisSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the CHEK2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Niraparib
Qian Qin
Phase 2CCC
Abiraterone Acetate
Qian Qin
Phase 2CCC
EXEMESTANE
Dana-Farber Cancer Institute
Phase 2CCC
PREDNISONE TABLETS
Qian Qin
Phase 2CCC
Olaparib
Beth Israel Deaconess Medical Center
Phase 2CCC
Docetaxel
Qian Qin
Phase 2CCC
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 2CCC

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Hormone Receptor Positive TumorDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →